By Amrutha Penumudi and Rosmi Shaji (Reuters) - Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs. Cubist shares were up 1.9 percent in extended trading. The drug, Zerbaxa, treats infections caused by gram-negative bacteria — a type of antibiotic-resistant pathogens, often called superbugs. ...
via Health News Headlines - Yahoo News http://ift.tt/1wM7KXP
via Health News Headlines - Yahoo News http://ift.tt/1wM7KXP
No comments:
Post a Comment